The estimated Net Worth of Jay Venkatesan is at least $4.22 Milion dollars as of 15 July 2022. Jay Venkatesan owns over 20,063 units of Exicure Inc stock worth over $369,095 and over the last 7 years he sold XCUR stock worth over $3,760,000. In addition, he makes $95,698 as Independent Director at Exicure Inc.
Jay has made over 6 trades of the Exicure Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 20,063 units of XCUR stock worth $9,028 on 15 July 2022.
The largest trade he's ever made was selling 400,000 units of Exicure Inc stock on 17 September 2021 worth over $3,760,000. On average, Jay trades about 59,899 units every 85 days since 2017. As of 15 July 2022 he still owns at least 238,126 units of Exicure Inc stock.
You can see the complete history of Jay Venkatesan stock trades at the bottom of the page.
Dr. Jay R. Venkatesan M.D. serves as Independent Director of the Company. has served as a member of our Board of Directors since March 2014. He serves as the chief executive officer and a director of Angion Biomedica Corp., a private clinical-stage biotechnology company, a position he has held since May 2018. Dr. Venkatesan serves as a member of the board of directors of Alpine Immune Sciences, Inc., a specialty pharmaceutical company, since November 2015, and he previously served as its president from July 2017 to August 2018 and its chief executive officer from November 2015 to June 2016. Prior to joining Alpine, Dr. Venkatesan served as the executive vice president and general manager of Oncothyreon, Inc. (now Cascadian Therapeutics) from August 2014 to May 2015 following Oncothyreon’s acquisition of Alpine Biosciences, where he served as co-founder and chief executive officer. Previously, Dr. Venkatesan was the founder, portfolio manager, and managing director of Ayer Capital Management LP, a global healthcare equity fund from January 2008 to December 2013. Prior to that, he was a director at Brookside Capital Partners LP from 2002 to 2007. Earlier in his career, Dr. Venkatesan was involved in healthcare investing at Partricof & Co. Ventures, Inc. from 1995 to 1996 and consulting at McKinsey & Company LP from 1993 to 1995. Dr. Venkatesan currently serves on the boards of directors of Transplant Genomics, Inc. and CellBioTherapy, Inc., and served on the board of directors of Iovance Biotherapeutics, Inc. (formerly Lion Biotechnologies) until March 2018. Dr. Venkatesan received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania, and a B.A. in Chemistry from Williams College. Our Board believes that Dr. Venkatesan’s experience in management and board positions in public and private biotechnology companies qualify him to serve on the Board.
As the Independent Director of Exicure Inc, the total compensation of Jay Venkatesan at Exicure Inc is $95,698. There are 6 executives at Exicure Inc getting paid more, with David Giljohann having the highest compensation of $785,462.
Jay Venkatesan is 48, he's been the Independent Director of Exicure Inc since 2014. There are 7 older and 4 younger executives at Exicure Inc. The oldest executive at Exicure Inc is David Walt, 67, who is the Independent Director.
Jay's mailing address filed with the SEC is C/O ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE, WA, 98102.
Over the last 6 years, insiders at Exicure Inc have traded over $4,850,172 worth of Exicure Inc stock and bought 7,217,940 units worth $10,705,021 . The most active insiders traders include Timothy P Walbert, Co., Ltd. Dgp oraz Usa, Inc. Cbi. On average, Exicure Inc executives and independent directors trade stock every 90 days with the average trade being worth of $928,360. The most recent stock trade was executed by Co., Ltd. Dgp on 29 February 2024, trading 3,400,000 units of XCUR stock currently worth $4,488,000.
exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
Exicure Inc executives and other stock owners filed with the SEC include: